Single injection of triamcinolone versus three repeated injections of bevacizumab for treatment of diabetic macular edema

Basit Öğe Kaydı
dc.contributor.authorTaş, Mehmet
dc.contributor.authorÖner, Veysi
dc.contributor.authorAlakuş, Mehmet Fuat
dc.contributor.authorTürkçü, Fatih Mehmet
dc.contributor.authorİşcan, Yalçın
dc.contributor.authorYüksel, Kemal
dc.date.accessioned2024-04-24T17:56:05Z
dc.date.available2024-04-24T17:56:05Z
dc.date.issued2013
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractTo compare the effect of a single intravitreal injection of triamcinolone acetonide versus three consecutive monthly intravitreal injections of bevacizumab for the treatment of diabetic macular edema (DME). Forty patients treated with a single intravitreal injection of 4 mg triamcinolone acetonide (triamcinolone group) were compared with 40 patients treated with three consecutive monthly intravitreal injections of 1.25 mg bevacizumab (bevacizumab group). The triamcinolone group showed a significant decrease in mean central retinal thickness (CRT) from 472.5 ?m ± 120.35 to 374.0 ?m ± 152.31 after 3 months (p < 0.001). The bevacizumab group also showed a significant reduction in CRT from 464.5 ?m ± 115.3 to 370.0 ?m ± 142.31 (p < 0.001). The triamcinolone group displayed an increase in best-corrected visual acuity (BCVA) following a single intravitreal triamcinolone acetonide injection from a mean of +0.70 ± 0.17 logMAR to a mean of +0.54 ± 0.38 logMAR after 3 months (p < 0.05). The bevacizumab group also showed an increase in BCVA following three injections of bevacizumab from a mean of +0.73 ± 0.28 logMAR to a mean of +0.57 ± 0.33 logMAR (p < 0.05). Statistical analysis showed no significant difference between both groups at 3 months. Our study showed that a single intravitreal injection of triamcinolone is as effective as three consecutive monthly intravitreal injections of bevacizumab for treatment of DME with regard to BCVA and CRT measured by optical coherence tomography. Despite the recent popularity of bevacizumab, three injections are no more effective than a single injection of triamcinolone for the treatment of DME.en_US
dc.identifier.citationTaş, M., Öner, V., Alakuş, M. F., Türkçü, F. M., İşcan, Y. ve Yüksel, K. (2013). Single injection of triamcinolone versus three repeated injections of bevacizumab for treatment of diabetic macular edema. International Ophthalmology, 33(4), 375-380.
dc.identifier.doi10.1007/s10792-012-9709-z
dc.identifier.endpage380en_US
dc.identifier.issn0165-5701
dc.identifier.issue4en_US
dc.identifier.pmid23334618
dc.identifier.scopus2-s2.0-84890179905
dc.identifier.scopusqualityQ2
dc.identifier.startpage375en_US
dc.identifier.urihttps://doi.org/10.1007/s10792-012-9709-z
dc.identifier.urihttps://hdl.handle.net/11468/23264
dc.identifier.urihttps://link.springer.com/article/10.1007/s10792-012-9709-z
dc.identifier.volume33en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.relation.ispartofInternational Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBevacizumaben_US
dc.subjectDiabetic macular edemaen_US
dc.subjectIntravitreal injectionen_US
dc.subjectTriamcinoloneen_US
dc.titleSingle injection of triamcinolone versus three repeated injections of bevacizumab for treatment of diabetic macular edemaen_US
dc.titleSingle injection of triamcinolone versus three repeated injections of bevacizumab for treatment of diabetic macular edema
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Single injection of triamcinolone versus three repeated injections of bevacizumab for treatment of diabetic macular edema.pdf
Boyut:
194.18 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu